Reuters logo
BRIEF-Respiratorius: FDA grants Orphan Drug Designation for VAL001
April 3, 2017 / 10:13 AM / 8 months ago

BRIEF-Respiratorius: FDA grants Orphan Drug Designation for VAL001

April 3 (Reuters) - RESPIRATORIUS AB (PUBL):

* SAYS HAS BEEN GRANTED ORPHAN DRUG DESIGNATION BY US FOOD AND DRUG ADMINISTRATION (FDA) FOR VALPROIC ACID FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA

* A CLINICAL PHASE I/IIA STUDY OF VAL001 IS UNDERWAY AND EXPECTED TO BE REPORTED IN H1 2018

Source text: bit.ly/2oQ0sBL

Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below